Anna Simon

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5335040/publications.pdf

Version: 2024-02-01

		50276	30922
141	10,887	46	102
papers	citations	h-index	g-index

145	145	145	10864
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Curation and expansion of Human Phenotype Ontology for defined groups of inborn errors of immunity. Journal of Allergy and Clinical Immunology, 2022, 149, 369-378.	2.9	16
2	Long-term efficacy and safety of canakinumab in patients with mevalonate kinase deficiency: results from the randomised Phase 3 CLUSTER trial. Rheumatology, 2022, 61, 2088-2094.	1.9	2
3	The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukinâ€1 Mediated Autoinflammatory Diseases: Cryopyrinâ€Associated Periodic Syndromes, Tumour Necrosis Factor Receptorâ€Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukinâ€1 Receptor Antagonist. Arthritis and Rheumatology, 2022,	5.6	14
4	The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist. Annals of the Rheumatic Diseases, 2022, 81, 907-921.	0.9	38
5	Immunoglobulin Replacement Therapy Versus Antibiotic Prophylaxis as Treatment for Incomplete Primary Antibody Deficiency. Journal of Clinical Immunology, 2021, 41, 382-392.	3.8	7
6	Optimal use of [18F]FDG-PET/CT in patients with fever or inflammation of unknown origin. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2021, 65, 51-58.	0.7	12
7	Phenotypic diversity, disease progression, and pathogenicity of <scp>MVK</scp> missense variants in mevalonic aciduria. Journal of Inherited Metabolic Disease, 2021, 44, 1272-1287.	3.6	17
8	Canakinumab improves patient-reported outcomes in children and adults with autoinflammatory recurrent fever syndromes: results from the CLUSTER trial. Clinical and Experimental Rheumatology, 2021, 39 Suppl 132, 51-58.	0.8	0
9	Canakinumab improves patient-reported outcomes in children and adults with autoinflammatory recurrent fever syndromes: results from the CLUSTER trial. Clinical and Experimental Rheumatology, 2021, 39, 51-58.	0.8	2
10	Complex medical history of a patient with a compound heterozygous mutation inC1QC. Lupus, 2019, 28, 1255-1260.	1.6	3
11	Defective Protein Prenylation in a Spectrum of Patients With Mevalonate Kinase Deficiency. Frontiers in Immunology, 2019, 10, 1900.	4.8	21
12	Exome sequencing in routine diagnostics: a generic test for 254 patients with primary immunodeficiencies. Genome Medicine, 2019, 11, 38.	8.2	49
13	Classification criteria for autoinflammatory recurrent fevers. Annals of the Rheumatic Diseases, 2019, 78, 1025-1032.	0.9	300
14	Mevalonate Kinase Deficiency. , 2019, , 315-327.		1
15	OP0254â€…CANAKINUMAB IMPROVES PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RECURRENT FEVER SYNDROMES: RESULTS FROM A PHASE 3 TRIAL (CLUSTER). , 2019, , .		0
16	An International Delphi Survey for the Definition of New Classification Criteria for Familial Mediterranean Fever, Mevalonate Kinase Deficiency, TNF Receptorâ€“associated Periodic Fever Syndromes, and Cryopyrin-associated Periodic Syndrome. Journal of Rheumatology, 2019, 46, 429-436.	2.0	16
17	Systemic Autoinflammatory Syndromes. , 2019, , 825-834.e1.		1
18	Decreased quality of life and societal impact of cryopyrin-associated periodic syndrome treated with canakinumab: a questionnaire based cohort study. Orphanet Journal of Rare Diseases, 2018, 13, 59.	2.7	11

#	Article	IF	Citations
19	Response to Jolobe: â€˜Molecular diagnostics in FUOâ€™. QJM - Monthly Journal of the Association of Physicians, 2018, 111, 211-211.	0.5	2
20	Long-term prognosis, treatment, and outcome of patients with fever of unknown origin in whom no diagnosis was made despite extensive investigation. Medicine (United States), 2018, 97, e11241.	1.0	20
21	Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. New England Journal of Medicine, 2018, 378, 1908-1919.	27.0	327
22	In silico validation of the Autoinflammatory Disease Damage Index. Annals of the Rheumatic Diseases, 2018, 77, 1599-1605.	0.9	27
23	THU0570â€…Long-term efficacy and safety of canakinumab in patients with colchicine-resistant fmf (CRFMF), traps and hids/mkd: results from the pivotal phase 3 cluster trial. , 2018, , .		2
24	Erythematous nodes, urticarial rash and arthralgias in a large pedigree with NLRC 4 â€related autoinflammatory disease, expansion of the phenotype. British Journal of Dermatology, 2017, 176, 244-248.	1.5	64
25	Development of the autoinflammatory disease damage index (ADDI). Annals of the Rheumatic Diseases, 2017, 76, 821-830.	0.9	68
26	Referral of patients with fever of unknown origin to an expertise center has high diagnostic and therapeutic value. QJM - Monthly Journal of the Association of Physicians, 2017, 110, 793-801.	0.5	22
27	International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors. Rheumatology, 2017, 56, 2102-2108.	1.9	84
28	Defective protein prenylation is a diagnostic biomarker of mevalonate kinase deficiency. Journal of Allergy and Clinical Immunology, 2017, 140, 873-875.e6.	2.9	29
29	Peri- and Postoperative Treatment with the Interleukin-1 Receptor Antagonist Anakinra Is Safe in Patients Undergoing Renal Transplantation: Case Series and Review of the Literature. Frontiers in Pharmacology, 2017, 8, 342.	3.5	23
30	Familial Autoinflammatory Syndromes. , 2017, , 1666-1684.e4.		2
31	A web-based collection of genotype-phenotype associations in hereditary recurrent fevers from the Eurofever registry. Orphanet Journal of Rare Diseases, 2017, 12, 167.	2.7	52
32	The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry. Arthritis and Rheumatology, 2016, 68, 2795-2805.	5.6	168
33	FRI0489â€…Canakinumab Improves Patient Reported Outcomes in Patients with Periodic Fever Syndromes: Table 1.. Annals of the Rheumatic Diseases, 2016, 75, 616.1-616.	0.9	2
34	FRI0488â€…A Phase Iii Pivotal Umbrella Trial of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes (Colchicine Resistant FMF, HIDS/MKD and TRAPS). Annals of the Rheumatic Diseases, 2016, 75, 615.2-616.	0.9	4
35	Prognosis of Good syndrome: mortality and morbidity of thymoma associated immunodeficiency in perspective. Clinical Immunology, 2016, 171, 12-17.	3.2	55
36	The challenge of autoinflammatory syndromes: with an emphasis on hyper-IgD syndrome. Rheumatology, 2016, 55, ii23-ii29.	1.9	12

#	Article	IF	Citations
37	Rheumatologic diseases as the cause of fever of unknown origin. Best Practice and Research in Clinical Rheumatology, 2016, 30, 789-801.	3.3	23
38	THU0569â€...Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes (Colchicine Resistant FMF, HIDS/MKD and TRAPS). Annals of the Rheumatic Diseases, 2016, 75, 397.3-398.	0.9	1
39	Anakinra Injection Site Reaction on FDG PET/CT. Clinical Nuclear Medicine, 2015, 40, 492-493.	1.3	3
40	Mastâ€cell interleukinâ€1Î², neutrophil interleukinâ€17 and epidermal antimicrobial proteins in the neutrophilic urticarial dermatosis in Schnitzler's syndrome. British Journal of Dermatology, 2015, 173, 448-456.	1.5	35
41	International experience of pregnancy outcomes in auto-inflammatory syndromes treated with Interleukin-1 inhibitors. Pediatric Rheumatology, 2015, 13, .	2.1	5
42	Successful kidney transplantation during anakinra treatment without complications. Pediatric Rheumatology, 2015, 13, .	2.1	0
43	Genetic and phenotypic characteristics of 114 patients with mevalonate kinase deficiency. Pediatric Rheumatology, 2015, 13, .	2.1	5
44	A novel mutation in NLRC4 in a large pedigree with an anakinra responsive autoinflammatory disease. Pediatric Rheumatology, 2015, 13, P30.	2.1	1
45	Fever of unknown origin. Clinical Medicine, 2015, 15, 280-284.	1.9	95
46	Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Annals of the Rheumatic Diseases, 2015, 74, 799-805.	0.9	215
47	Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever. Annals of the Rheumatic Diseases, 2015, 74, 635-641.	0.9	145
48	ATP-Induced IL-1ÃŽÂ² Specific Secretion: True Under Stringent Conditions. Frontiers in Immunology, 2015, 6, 54.	4.8	43
49	Marked variability in clinical presentation and outcome of patients with C1q immunodeficiency. Journal of Autoimmunity, 2015, 62, 39-44.	6.5	33
50	TLR2/TLR4-dependent exaggerated cytokine production in hyperimmunoglobulinaemia D and periodic fever syndrome. Rheumatology, 2015, 54, 363-368.	1.9	45
51	Recommendations for the management of autoinflammatory diseases. Annals of the Rheumatic Diseases, 2015, 74, 1636-1644.	0.9	239
52	Th17 cytokine deficiency in patients with Aspergillus skull base osteomyelitis. BMC Infectious Diseases, 2015, 15, 140.	2.9	23
53	Hyper-IgD syndrome/mevalonate kinase deficiency: what is new?. Seminars in Immunopathology, 2015, 37, 371-376.	6.1	47
54	The role of interleukin-1 beta in the pathophysiology of Schnitzlerâ€™s syndrome. Arthritis Research and Therapy, 2015, 17, 187.	3.5	45

#	Article	IF	Citations
55	Myeloid lineageâ€“restricted somatic mosaicism of NLRP3 mutations in patients with variant Schnitzler syndrome. Journal of Allergy and Clinical Immunology, 2015, 135, 561-564.e4.	2.9	115
56	Evidence based recommendations for diagnosis and treatment of tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS). Pediatric Rheumatology, 2014, 12, .	2.1	0
57	Evidence based recommendations for genetic diagnosis of Familial Mediterranean Fever. Pediatric Rheumatology, 2014, 12, .	2.1	7
58	The discriminative capacity of soluble Toll-like receptor (sTLR)2 and sTLR4 in inflammatory diseases. BMC Immunology, 2014, 15, 55.	2.2	54
59	Evidence based recommendations for diagnosis and management of mevalonate kinase defiency (MKD). Pediatric Rheumatology, 2014, 12, .	2.1	0
60	Validation of the Auto-Inflammatory Diseases Activity Index (AIDAI) for hereditary recurrent fever syndromes. Annals of the Rheumatic Diseases, 2014, 73, 2168-2173.	0.9	120
61	Comment on â€œPower of Rare Diseases: Found in Translationâ€. Science Translational Medicine, 2014, 6, 219le1.	12.4	3
62	Cytokine Production Assays Reveal Discriminatory Immune Defects in Adults with Recurrent Infections and Noninfectious Inflammation. Vaccine Journal, 2014, 21, 1061-1069.	3.1	5
63	Mevalonate kinase deficiency nomenclature. Rheumatology International, 2014, 34, 295-296.	3.0	2
64	The Concept of Autoinflammatory Diseases. , 2014, , 39-50.		0
65	Cholesterol Metabolism and Immunity. New England Journal of Medicine, 2014, 371, 1933-1935.	27.0	48
66	MEFVmutations affecting pyrin amino acid 577 cause autosomal dominant autoinflammatory disease. Annals of the Rheumatic Diseases, 2014, 73, 455-461.	0.9	101
67	Circulating galectin-3 in infections and non-infectious inflammatory diseases. European Journal of Clinical Microbiology and Infectious Diseases, 2013, 32, 1605-1610.	2.9	38
68	Mutations in the Mevalonate Kinase (MVK) Gene Cause Nonsyndromic Retinitis Pigmentosa. Ophthalmology, 2013, 120, 2697-2705.	5.2	56
69	Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Annals of the Rheumatic Diseases, 2013, 72, 678-685.	0.9	350
70	Long chain fatty acid (Lcfa) abnormalities in hyper Igd syndrome (Hids) and familial Mediterranean fever (Fmf): New insight into heritable periodic fevers. Molecular Genetics and Metabolism, 2013, 108, 166-171.	1.1	4
71	Unexplained recurrent fever: when is autoinflammation the explanation?. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 285-296.	5.7	35
72	OR5-002 â€“ In vitro studies in Schnitzlerâ€™s syndrome. Pediatric Rheumatology, 2013, 11, .	2.1	0

#	Article	IF	Citations
73	OR7-002 â€“ Pyrin 577 mutations in dominant autoinflammation. Pediatric Rheumatology, 2013, 11, .	2.1	1
74	PW02-034 - NLRP3 mosaicism detection in CAPS using NGS. Pediatric Rheumatology, 2013, 11, .	2.1	0
75	PW02-035 - A role for thermo-TRP channels in innate immunity?. Pediatric Rheumatology, 2013, 11, .	2.1	1
76	OR11-002 - Mutations in MVK cause non-syndromic RP. Pediatric Rheumatology, 2013, 11, .	2.1	0
77	PW03-006 - IL-1-B inhibition in Schnitzlerâ€™s syndrome. Pediatric Rheumatology, 2013, 11, .	2.1	0
78	PW03-007 - NLRP3 genetic variants in Schnitzlerâ€™s syndrome. Pediatric Rheumatology, 2013, 11, .	2.1	1
79	Schnitzler's syndrome: diagnosis, treatment, and followâ€up. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 562-568.	5.7	224
80	Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome. Annals of the Rheumatic Diseases, 2013, 72, 1634-1638.	0.9	90
81	THU0377â€…Efficacy, safety and pharmacokinetics of the anti-interleukin-1 beta antibody canakinumab in patients with schnitzler syndrome. Annals of the Rheumatic Diseases, 2013, 71, 283.1-283.	0.9	0
82	OP0175â€…The eurofever registry for autoinflammatory disease: Update on enrollment after 2 years. Annals of the Rheumatic Diseases, 2013, 71, 114.1-114.	0.9	0
83	Familial Autoinflammatory Syndromes. , 2013, , 1597-1615.e4.		0
84	Systemic autoinflammatory syndromes. , 2013, , 728-739.		0
85	Pattern recognition receptors in infectious skin diseases. Microbes and Infection, 2012, 14, 881-893.	1.9	23
86	How not to miss autoinflammatory diseases masquerading as urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 1465-1474.	5.7	74
87	An International registry on Autoinflammatory diseases: the Eurofever experience. Annals of the Rheumatic Diseases, 2012, 71, 1177-1182.	0.9	158
88	Strong induction of <scp>AIM</scp>2 expression in human epidermis in acute and chronic inflammatory skin conditions. Experimental Dermatology, 2012, 21, 961-964.	2.9	71
89	Pattern Recognition Receptors in Immune Disorders Affecting the Skin. Journal of Innate Immunity, 2012, 4, 225-240.	3.8	13
90	Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nature Reviews Drug Discovery, 2012, 11, 633-652.	46.4	1,479

#	Article	IF	Citations
91	Successful canakinumab treatment identifies IL-1Î² as a pivotal mediator in Schnitzler syndrome. Journal of Allergy and Clinical Immunology, 2011, 128, 1352-1354.	2.9	49
92	Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). Journal of Experimental Medicine, 2011, 208, 519-533.	8.5	749
93	Variable expression and treatment of PAPA syndrome. Annals of the Rheumatic Diseases, 2011, 70, 1168-1170.	0.9	42
94	Audiometric characteristics of a Dutch family with Muckle-Wells syndrome. Hearing Research, 2011, 282, 243-251.	2.0	11
95	Effects of the Histone Deacetylase Inhibitor ITF2357 in Autoinflammatory Syndromes. Molecular Medicine, 2011, 17, 363-368.	4.4	23
96	Hyper-IgD syndrome or mevalonate kinase deficiency. Current Opinion in Rheumatology, 2011, 23, 419-423.	4.3	42
97	A preliminary score for the assessment of disease activity in hereditary recurrent fevers: results from the AIDAI (Auto-Inflammatory Diseases Activity Index) Consensus Conference. Annals of the Rheumatic Diseases, 2011, 70, 309-314.	0.9	70
98	On-demand anakinra treatment is effective in mevalonate kinase deficiency. Annals of the Rheumatic Diseases, 2011, 70, 2155-2158.	0.9	142
99	Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 9801-9806.	7.1	177
100	Blocking IL-1Î² to slow down progression of ALS?. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 12741-12742.	7.1	11
101	IL-1Î² Processing in Host Defense: Beyond the Inflammasomes. PLoS Pathogens, 2010, 6, e1000661.	4.7	427
102	A Clinical Criterion to Exclude the Hyperimmunoglobulin D Syndrome (Mild Mevalonate Kinase) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 30	2.0	45
103	Abnormal IgD and IgA1 O-glycosylation in hyperimmunoglobulinaemia D and periodic fever syndrome. Clinical and Experimental Medicine, 2009, 9, 291-296.	3.6	7
104	Dysregulation of innate immunity: hereditary periodic fever syndromes. British Journal of Haematology, 2009, 144, 279-302.	2.5	37
105	Cathepsin D activity protects against development of type AA amyloid fibrils. European Journal of Clinical Investigation, 2009, 39, 412-416.	3.4	16
106	Horror Autoinflammaticus: The Molecular Pathophysiology of Autoinflammatory Disease. Annual Review of Immunology, 2009, 27, 621-668.	21.8	970
107	Recurrent febrile syndromesâ€"what a rheumatologist needs to know. Nature Reviews Rheumatology, 2009, 5, 249-256.	8.0	41
108	Familial Autoinflammatory Syndromes. , 2009, , 1863-1882.		1

#	Article	IF	Citations
109	Complete remission of severe idiopathic cold urticaria on interleukin-1 receptor antagonist (anakinra). Netherlands Journal of Medicine, 2009, 67, 302-5.	0.5	40
110	Response to â€œSchnitzler's Syndrome: A True Auto-Inflammatory Disorder?â€• Seminars in Arthritis and Rheumatism, 2008, 38, 164.	3.4	0
111	IL-1 blockade in Schnitzler syndrome: Ex vivo findings correlate with clinical remission. Journal of Allergy and Clinical Immunology, 2008, 121, 260-262.	2.9	86
112	Drosomycin-Like Defensin, a Human Homologue ofDrosophila melanogasterDrosomycin with Antifungal Activity. Antimicrobial Agents and Chemotherapy, 2008, 52, 1407-1412.	3.2	32
113	Increased susceptibility of serum amyloid A 1.1 to degradation by MMP-1: potential explanation for higher risk of type AA amyloidosis. Rheumatology, 2008, 47, 1651-1654.	1.9	37
114	Lovastatin inhibits formation of AA amyloid. Journal of Leukocyte Biology, 2008, 83, 1295-1299.	3.3	17
115	Long-Term Follow-Up, Clinical Features, and Quality of Life in a Series of 103 Patients With Hyperimmunoglobulinemia D Syndrome. Medicine (United States), 2008, 87, 301-310.	1.0	344
116	Pathogenesis of familial periodic fever syndromes or hereditary autoinflammatory syndromes. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2007, 292, R86-R98.	1.8	118
117	Comment on: Schnitzlers syndrome exacerbation after anti-TNF treatment. Rheumatology, 2007, 46, 1741-1741.	1.9	7
118	Defective apoptosis of peripheral-blood lymphocytes in hyper-IgD and periodic fever syndrome. Blood, 2007, 109, 2416-2418.	1.4	36
119	Approach to the diagnosis of hereditary autoinflammatory syndromes. Future Rheumatology, 2007, 2, 5-8.	0.2	1
120	AL amyloidosis enhances development of amyloid A amyloidosis. British Journal of Dermatology, 2007, 156, 748-749.	1.5	12
121	Schnitzler Syndrome: Beyond the Case Reports: Review and Follow-Up of 94 Patients with an Emphasis on Prognosis and Treatment. Seminars in Arthritis and Rheumatism, 2007, 37, 137-148.	3.4	228
122	Pseudonormalisation of the T wave: old wine?. Netherlands Heart Journal, 2007, 15, 257-259.	0.8	7
123	Beneficial response to anakinra and thalidomide in Schnitzler's syndrome. Annals of the Rheumatic Diseases, 2006, 65, 542-544.	0.9	126
124	Hot and hobbling with hives: Schnitzler syndrome. Clinical Immunology, 2006, 119, 131-134.	3.2	21
125	Approach to genetic analysis in the diagnosis of hereditary autoinflammatory syndromes. Rheumatology, 2006, 45, 269-273.	1.9	79
126	Familial Mediterranean feverâ€”a not so unusual cause of abdominal pain. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2005, 19, 199-213.	2.4	41

#	Article	IF	Citations
127	Hereditary periodic fever and reactive amyloidosis. Clinical and Experimental Medicine, 2005, 5, 87-98.	3.6	111
128	Serum amyloid A serum concentrations and genotype do not explain low incidence of amyloidosis in Hyper-IgD syndrome. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2005, 12, 115-119.	3.0	17
129	Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. Netherlands Journal of Medicine, 2005, 63, 260-4.	0.5	134
130	Mevalonate kinase deficiency. Neurology, 2004, 62, 994-997.	1.1	142
131	Effect of inflammatory attacks in the classical type hyper-IgD syndrome on immunoglobulin D, cholesterol and parameters of the acute phase response. Journal of Internal Medicine, 2004, 256, 247-253.	6.0	34
132	Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clinical Pharmacology and Therapeutics, 2004, 75, 476-483.	4.7	190
133	Beneficial response to interleukin 1 receptor antagonist in traps. American Journal of Medicine, 2004, 117, 208-210.	1.5	146
134	A founder effect in the hyperimmunoglobulinemia D and periodic fever syndrome. American Journal of Medicine, 2003, 114, 148-152.	1.5	55
135	Pseudothrombocytopenia: a report of a new method to count platelets in a patient with EDTA- and temperature-independent antibodies of the IgM type. European Journal of Haematology, 2002, 69, 243-247.	2.2	25
136	Familial periodic fever and amyloidosis due to a new mutation in the TNFRSF1A gene. American Journal of Medicine, 2001, 110, 313-316.	1.5	40
137	Molecular Analysis of the Mevalonate Kinase Gene in a Cohort of Patients with the Hyper-IgD and Periodic Fever Syndrome: Its Application as a Diagnostic Tool. Annals of Internal Medicine, 2001, 135, 338.	3.9	81
138	Molecular analysis of MVK mutations and enzymatic activity in hyper-IgD and periodic fever syndrome. European Journal of Human Genetics, 2001, 9, 260-266.	2.8	182
139	Genetic Analysis as a Valuable Key to Diagnosis and Treatment of Periodic Fever. Archives of Internal Medicine, 2001, 161, 2491-2493.	3.8	27
140	Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper-IgD and periodic fever syndrome: a randomized, double-blind, placebo-controlled trial. Journal of Pharmacology and Experimental Therapeutics, 2001, 298, 1221-6.	2.5	46
141	Pseudohypoparathyroidism type Ia Albright hereditary osteodystrophy: a model for research on G protein-coupled receptors and genomic imprinting. Netherlands Journal of Medicine, 2000, 56, 100-109.	0.5	14